GPC1 and glioblastoma: Adjuvant radiochemotherapy with temozolomide results in increased expression of glypican-1 (GPC-1), which is correlated with shorter overall survival of GBM patients [35], and affects HS content and distribution as well as causing increased intertumor heterogeneity of HPSE in relapsed tumors [36].